Drug interactions
Idecabtagene vicleucel + Ocrelizumab
Severity: Major
Idecabtagene vicleucel and Ocrelizumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ocrelizumab depletes B cells and adds to the immunosuppression and cytopenias already expected after CAR-T therapy. Together they can raise the risk of serious infections.
What this interaction means in plain words
Idecabtagene vicleucel and Ocrelizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Idecabtagene vicleucel belongs to Oncology; Ocrelizumab belongs to Central Nervous System.
Why it happens
Additive immunosuppression through anti-CD20 B-cell depletion combined with lymphodepleting chemotherapy and CAR-T related cytopenias and hypogammaglobulinemia.
What to do
Avoid combining where possible and coordinate timing of ocrelizumab with the cell-therapy team. If used, monitor closely for infection and immunoglobulin levels and give prophylaxis as per protocol.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Idecabtagene vicleucel and Ocrelizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ocrelizumab
- Adenovirus types 4 and 7 live + Ocrelizumab Contraindicated
- Influenza virus vaccine quadrivalent intranasal + Ocrelizumab Contraindicated
- Measles mumps and rubella vaccine live + Ocrelizumab Contraindicated
- Measles mumps rubella and varicella vaccine live + Ocrelizumab Contraindicated
- Measles vaccine + Ocrelizumab Contraindicated
- Anti-thymocyte + Ocrelizumab Major
Other interactions of Idecabtagene vicleucel
Frequently asked questions
Can I take Idecabtagene vicleucel with Ocrelizumab?
MediHelp rates the interaction as major. Idecabtagene vicleucel and Ocrelizumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Ocrelizumab depletes B cells and adds to the immunosuppression and cytopenias already expected after CAR-T therapy. Together they can raise the risk of serious infections.
How serious is the interaction between Idecabtagene vicleucel and Ocrelizumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible and coordinate timing of ocrelizumab with the cell-therapy team. If used, monitor closely for infection and immunoglobulin levels and give prophylaxis as per protocol.
What other medicines interact with Ocrelizumab?
MediHelp also lists interactions of Ocrelizumab with, for example, Adenovirus types 4 and 7 live, Influenza virus vaccine quadrivalent intranasal, Measles mumps and rubella vaccine live. The full list is on the Ocrelizumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
